BioCanada

Found 27,301 articles

• FDA Approves Aurinia Pharmaceuticals’ LUPKYNIS™ (voclosporin) for Adult Patients with Active Lupus Nephritis

  1/23/2021

  - LUPKYNIS is the first FDA-approved oral therapy for lupus nephritis (LN), a condition that causes irreversible kidney damage and increases the risk of kidney failure, cardiac events, and death - - LUPKYNIS demonstrated significantly improved renal response rates compared to typical standard-of-care (SoC) in clinical trials

• FSD Pharma Sets Date for Annual Meeting

  1/22/2021

  FSD Pharma Inc. (Nasdaq:HUGE) (CSE:HUGE) (“FSD Pharma” or the “Company”) today announced that it will hold its annual meeting of shareholders (the “Meeting”) on June 29, 2021. The Meeting will address normal course matters, including the presentation of the Company’s audited financial statements, as well as matters contained in a requisition for a special meeting submitted to the Company by certain shareholders of the Compa

• XPhyto Provides Comments on Promotional and Marketing Activity

  1/22/2021

  XPhyto Therapeutics Corp at the request of OTC Markets, is providing the following comments regarding recent promotional activity with respect to the Corporation. The Corporation has been listed on the Canadian Securities Exchange from July 2019.

• /R E P E A T -- Notice to the media - COVID-19 Update (January 22, 2021) - Ministers and Government of Canada officials to hold a news conference on coronavirus disease/

  1/22/2021

   Ministers and Government of Canada officials will hold a news conference to provide an update on coronavirus disease (COVID-19). Date January 22, 2021 Time 12:30 PM (EST) Location The news conference will be held virtually. Journalists who wish to ask questions can do so by teleconference. Toll-free ( Canada /US) di

• Asia Green Biotechnology Corp. Announces Appointment of Alisdair Leeson To Board of Directors

  1/22/2021

  Asia Green Biotechnology Corp. ("AGB" or the "Company") (CSE:ASIA), announced today that, subject to regulatory approval, Mr. Alisdair Leeson, CA, has been appointed as a member of the Board of Directors.

• BirchBioMed Inc. Announces Positive Topline Data from Phase 2 Study of FS2 for Treatment of Keloid Scars

  1/22/2021

  BirchBioMed Inc., a clinical-stage immunology company focused on the prevention and reduction of immunological fibrotic conditions and defects in the immune system, has announced statistically significant, positive results of a double-blind study

• Havn Life Sciences Announces Inclusion in First Psychedelic Exchange Traded Fund

  1/22/2021

  Havn Life Sciences Inc. (CSE: HAVN )(OTC PINK: HAVLF )(FSE: 5NP ) a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce that it will be included in the First Psychedelics Exchange Traded Fund. The ETF will begin traded on the Neo Exchange on January 26, 2021.

• Algernon Pharmaceuticals Provides Final Summary on Accelerated Warrants

  1/22/2021

  Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to provide a final summary of the common share purchase warrants of the Company (the “November Warrants”), that were issued on November 1, 2019.

• Revive Therapeutics Included in First Psychedelic Exchange Traded Fund

  1/22/2021

  Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it is one of the seventeen companies in the U.S. and Canada that will be included in the First Psychedelics Exchange Traded Fund, which is managed by Horizons ETF Management.

• Theralase Expands Intellectual Property Portfolio

  1/22/2021

  Theralase Technologies Inc. ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds and their associated drug formulations used to destroy various cancers, bacteria and viruses safely and effectively is pleased to announce that the Company has expanded its Intellectual property portfolio

• Entheon Biomedical to be Included in First North American Psychedelic ETF

  1/22/2021

  Vancouver, British Columbia--(Newsfile Corp. - January 22, 2021) -  Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce its inclusion in the Horizon North American Psychedelic ETF, the first ever psychedelic ETF of its kind.

• Hemostemix Announces the Bread Contract with the Department of Foreign Affairs, Trade & Development Canada

  1/22/2021

  Calgary, Alberta--(Newsfile Corp. - January 22, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXD) ("Hemostemix" or the "Company") is pleased to announce it has signed the Building Relationships Entrepreneurs & Dealmakers (BREAD) contract with the Department of Foreign Affairs, Trade and Development.

• Binovi Technologies Q3 2020 Revenue Up, Increasing Top-Line and Gross Margin Results

  1/21/2021

  Binovi Technologies Corp. a leader in neuro-vision performance technology, reports results for the Company's fiscal third quarter, ended November 30, 2020.

• Crescita Announces Filing of New Medical Device License

  1/21/2021

  Crescita Therapeutics Inc. and, a commercial dermatology, announced that Laboratoires FILLMED has submitted a New Medical Device License application for the ART FILLER® range of products.

• Federal PMPRB Drug Pricing Rules Already Stopping What Canadians Want: Access to New Cancer Medicines and Other Treatments as Soon as Possible

  1/21/2021

  Survey of pharmaceutical executives confirms almost all companies will delay new product launches; more than one-third already have

• Reaching new heights by working together: Innovative industry partnership using artificial intelligence to improve survival rates of cancer diagnosed patients

  1/21/2021

  The McGill University Health Centre Foundation and MEDTEQ+ are proud to announce a new partnership with the Research Institute of the McGill University Health Centre, MIMs, and Caprion-HistoGeneX, respective leaders in cancer research, artificial intelligence, and precision medicine, to increase survival of stage IV colorectal cancer patients.

• Medexus Submits Application to List on the NasdaqManagement to host investor update webinar on January 25th at 2pm Eastern

  1/21/2021

  Medexus Pharmaceuticals Inc. (the “ Company ” or “Medexus ”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731)   announced today that it has submitted its application to list on The Nasdaq Capital Market® (the “ Nasdaq ”). Ken d’Entremont, Chief Executive Officer of Medexus, commented, “The submission of our application to list on the Nasdaq marks a significant milestone for Medexus.

• BetterLife Selects CRO to Conduct Clinical Trials for AP-003 in COVID-19 Cases in Indonesia

  1/21/2021

  BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech focused on the development and commercialization of cutting-edge treatments in mental disorders and viral infections, is pleased to announce that it has engaged Equilab International to manage the upcoming clinical trials for its proprietary formulation of Interferon alpha2b (AP-003) in mild to moderate cases of COVID-19. BetterLife b

• AbCellera-Discovered Antibody Prevented COVID-19 in Nursing Homes and Reduced Risks by up to 80% for Residents

  1/21/2021

  AbCellera (Nasdaq: ABCL) today announced that bamlanivimab (LY-CoV555), a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities. Lilly’s Phase 3 BLAZE-2 COVID-19 prevention trial was conducted in partnership with the National Institute of Allergy and Infe

• Government of Canada Invests in Dementia Data and Community-based Projects

  1/21/2021

  The Honourable Patty Hajdu, Minister of Health, announced six new initiatives that will help implement Canada's national dementia strategy.